Sanofi intends to buy Inhibrx, Inc., bringing a promising rare disease candidate targeting Alpha-1 Antitrypsin Deficiency into its portfolio.

Strand Therapeutics recently revealed that the FDA has approved its request to commence a Phase 1 clinical trial, marking the initial human study of STX-001.

Gilead Sciences' EVOKE-01 Phase 3 Trial for Metastatic NSCLC Fails to Achieve Primary Endpoint: A Comparison of Trodelvy and Docetaxel.

Sandoz Finalizes USD 170 Million Purchase of Coherus BioSciences' Biosimilar Drug CIMERLI* (ranibizumab-eqrn) in the US

BioNTech and DualityBio have launched a critical Phase 3 study for their therapeutic agent BNT323/DB-1303, targeting advanced breast cancer.

NK CellTech has received the green light from the Food and Drug Administration (FDA) to initiate clinical trials for its therapy, NK010.

ProMIS Neurosciences Inc. has declared the identification of a premier vaccine contender, PMN400.

AC Immune SA to Reclaim Global Ownership of Two Therapeutic Antibodies Post-Partnership with Genentech and Roche.

Ionis reveals encouraging preliminary outcomes from the third phase of the OASIS-HAE trial, examining the experimental compound donidalorsen in individuals with genetic angioedema.

In the CheckMate -8HW study, the combination of Opdivo and Yervoy reduced the likelihood of disease advancement or fatality in patients with MSI-H/dMMR metastatic colorectal cancer by 79% when compared to chemotherapy.

BALVERSA® gains complete sanction from the U.S. FDA to cure bladder cancer in advanced or metastatic stages with specific genetic changes.

Merck Sharp & Dohme (MSD) and Harpoon Therapeutics announced a deal for MSD to purchase Harpoon at $23/share, totaling around $680 million in equity.